Prestige Biopharma Group

Prestige Biopharma is a Singapore-based biopharmaceutical company specializing in the development of biosimilars and first-in-class antibody therapeutics. The company's lead product, Tuznue (HD201), is a trastuzumab biosimilar that has received marketing authorization in Europe and the United Kingdom for the treatment of HER2-positive breast and gastric cancers. Beyond its biosimilar portfolio, Prestige is advancing a pipeline of innovative biologics, most notably PBP1510, an anti-PAUF monoclonal antibody for pancreatic cancer which has received Orphan Drug Designation from the FDA, EMA, and MFDS. The group operates a vertically integrated model, encompassing R&D centers in Singapore and South Korea, and large-scale manufacturing through its affiliate, Prestige Biologics. This integration allows the company to manage the full value chain from discovery to commercial production. Prestige Biopharma is publicly listed on the Korea Exchange and continues to expand its global footprint through strategic partnerships for distribution and commercialization.